Forever Labs

Steven Klausenitzer was working on a cryptocurrency startup called CoinAmp when his co-founder Dr. Mark Katakowski called with a frustration that sparked the entire company. Mark, who had spent his entire career studying stem cells and had even applied for NIH grants to research them, was turning 40 and couldn't find anyone willing to store his own stem cells for future use. Research had shown that reintroducing young stem cells into aging mice extended their lifespans by 16-20%, yet there was no commercial service available. Steven realized the perfect marriage of expertise: Mark's deep scientific knowledge combined with his own business development and team leadership background from 15 years at Fortune 500 companies like American Express.

Forever Labs went through Y Combinator and launched with an elegant model. Customers visit forever labs.com, select a procedure price ($2,500 upfront), choose an annual storage plan ($250/year recurring or $7,000 lifetime), then pick from credentialed physicians in their state. The company doesn't run its own clinics—instead, it partners with top orthopedic and plastic surgeons from Harvard, Stanford, Princeton, Yale, Duke, and Michigan across nine states. The procedure itself is a 15-minute outpatient bone marrow aspiration from the hip—essentially an "advanced blood draw" that patients rate as a 2 out of 10 on the pain scale. The harvested 60cc of bone marrow gets processed in Ann Arbor, Michigan, then stored in liquid nitrogen at a bio repository in Franklin, Massachusetts in nine separate aliquots.

By the time of this podcast, Forever Labs had acquired nearly 200 paying customers who weren't pre-paying or getting free trials—they were writing real checks. The math was straightforward: ~200 customers × $2,500+ in upfront fees = roughly $400,000 in revenue, plus approximately $45,000 in monthly recurring revenue from annual storage fees (accounting for some customers choosing the lifetime plan). What impressed Steven most was that these early customers were naturally referring friends and family, creating organic word-of-mouth growth. Geographic patterns emerged: in conservative markets like Michigan and North Carolina, customers were driven by practical concerns—family histories of cardiovascular disease, osteoarthritis, or rheumatoid arthritis. In San Francisco and LA, the motivation was pure longevity optimization and the social signaling of being part of the life-extension movement.

The company's biggest insight was distribution through credentialed physicians rather than company-owned clinics. This unlocked two advantages: it gave customers confidence in the procedure while simultaneously building a nationwide longevity physician network. The recurring revenue model worked better than expected—the choice between annual and lifetime storage meant customers committed long-term. The company also attracted the right early adopters: wealthy, health-conscious individuals in major metros who could pay $2,500-$7,000 upfront and understood the moonshot vision. What likely helped: Y Combinator backing, which signaled legitimacy; the partnership with top-tier universities and teaching hospitals; and the simple, direct value prop (store your young cells, access them later for longevity treatments).

Forever Labs has raised $2 million in funding and established operations across nine states with the highest-credentialed physician network in the country. Their shorter-term play targets the 500+ clinical trials already using stored stem cells to treat cardiovascular disease, stroke, and Alzheimer's—conditions where younger stem cells are proven more effective. The moonshot is "escape velocity": as Steven explained using the Model T analogy, humans weren't built to last a century, but with proper cellular maintenance and replacement of damaged parts (the same way a hundred-year-old Model T still runs if maintained properly), aging could become optional. At 40, Steven's own stem cells are stored at age 38, ready to be reintroduced intravenously at future points to reconstitute his immune system, blood, and connective tissue.